Rabitec

Rabies vaccine (live, oral) for foxes and raccoon dogs

Table of contents

Opinion

On 23 January 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion*, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Rabitec. The marketing authorisation holder for this veterinary medicinal product is IDT Biologika GmbH.

Rabitec is currently authorised as an oral suspension for the active immunization of foxes and raccoon dogs against rabies to prevent infection and mortality. The variation concerns extending the duration of immunity of the product from 6 to 12 months.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.


*Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Rabitec
Agency product number
EMEA/V/C/004387
International non-proprietary name (INN) or common name
  • Rabies vaccine (live, oral) for foxes and raccoon dogs
Species
Red foxes (Vulpes vulpes)
Raccoon dogs (Nyctereutes procyonoides)
Active substance
  • attenuated live rabies vaccine virus, strain SPBN GASGAS
Date opinion adopted
23/01/2020
Company name
IDTBiologika GmbH
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating